What You Should Know:
– iRhythm Technologies, a leader in digital healthcare, has announced a strategic partnership with BioIntelliSense, a continuous health monitoring company. The collaboration aims to develop and commercialize advanced cardiac monitoring technologies.
– BioIntelliSense has granted iRhythm an exclusive license to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use in iRhythm’s cardiac monitoring.
– BioIntelliSense will receive an upfront payment and may be eligible for additional consideration based on future milestones.
Partnership Impact
The partnership between iRhythm and BioIntelliSense has the potential to:
- Enhance cardiac monitoring: BioIntelliSense’s advanced technology can improve the accuracy and effectiveness of cardiac monitoring.
- Expand product offerings: iRhythm can expand its product portfolio with new cardiac monitoring solutions.
- Drive growth: The partnership could lead to increased revenue and market share for iRhythm.
“As a natural complement to iRhythm’s leading ambulatory cardiac monitoring platform, BioIntelliSense’s multiparameter sensing technologies position us to significantly expand the capabilities of our product platform over the next several years,” said Quentin Blackford, iRhythm’s President and CEO. “We believe that the licensed technology from BioIntelliSense can advance our premium positioning within ACM and further enables us to enter other adjacent indications such as obstructive sleep apnea over time. By incorporating medical grade, connected, multi-sensor capabilities, we believe iRhythm will be well positioned to deliver broad clinical insights that improve patient outcomes, enhance clinical and operational efficiency, and reduce costs to the healthcare system. We look forward to collaborating with the BioIntelliSense team to accelerate the next chapter of connected patient care.”
